MK-677 Dosage and Protocols
MK-677 dosage protocols reported in published research, plus reconstitution and storage.
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published clinical and preclinical research protocols. MK-677 is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation. All doses above are reported from published research protocols. Refer to the cited studies in the Research section above for original source data.
Reported protocol doses
Standard dose10–25 mg
Frequencyonce daily
Routesoral
Doses shown are those reported in published research, not a recommendation.
References
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. · Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR · 1998
- Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. · Nass R, Pezzoli SS, Oliveri MC, Patrie J, Harman SM, Carlson OD, Egan JM, Evans WS, Veldhuis JD, Thorner MO · 2008
- Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. · Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ · 1999
- Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. · Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ · 2001
- Ibutamoren | C27H36N4O5S | CID 9576836 - PubChem - NIH